Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.

The British Journal of Surgery
R F D van la ParraH M Kuerer

Abstract

Patients with triple-negative breast cancer (TNBC) and a pathological complete response (pCR) after neoadjuvant chemotherapy may be suitable for non-surgical management. The goal of this study was to identify baseline clinicopathological variables that are associated with residual disease, and to evaluate the effect of neoadjuvant chemotherapy on both the invasive and ductal carcinoma in situ (DCIS) components in TNBC. Patients with TNBC treated with neoadjuvant chemotherapy followed by surgical resection were identified. Patients with a pCR were compared with those who had residual disease in the breast and/or lymph nodes. Clinicopathological variables were analysed to determine their association with residual disease. Of the 328 patients, 36·9 per cent had no residual disease and 9·1 per cent had residual DCIS only. Patients with residual disease were more likely to have malignant microcalcifications (P = 0·023) and DCIS on the initial core needle biopsy (CNB) (P = 0·030). Variables independently associated with residual disease included: DCIS on CNB (odds ratio (OR) 2·46; P = 0·022), T2 disease (OR 2·40; P = 0·029), N1 status (OR 2·03; P = 0·030) and low Ki-67 (OR 2·41; P = 0·083). Imaging after neoadjuvant chemotherapy had ...Continue Reading

References

Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KuererS E Singletary
Jul 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chafika MazouniLajos Pusztai
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Jul 14, 2009·Annals of Surgical Oncology·Lisa WiechmannMonica Morrow
Jul 2, 2010·Cancer Chemotherapy and Pharmacology·Hiroko MasudaToshimasa Tsujinaka
Mar 16, 2012·Applied Immunohistochemistry & Molecular Morphology : AIMM·James A KrausRohit Bhargava
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Jul 13, 2013·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·D ReaA Francis
Oct 19, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B GerberUNKNOWN German Breast Group Investigators
Jul 2, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Olivier HumbertFrançois Brunotte
Mar 10, 2016·Breast Cancer Research : BCR·Raquel F D van la Parra, Henry M Kuerer
Nov 9, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Joerg HeilMichael Golatta
Jun 1, 2017·The New England Journal of Medicine·Norikazu MasudaMasakazu Toi
Sep 25, 2017·The Breast : Official Journal of the European Society of Mastology·P E R SpronkC H Smorenburg

❮ Previous
Next ❯

Citations

Dec 1, 2018·Molecular Oncology·Nerina DenaroCristiana Lo Nigro
Jul 7, 2018·Drug Delivery and Translational Research·Sumayah Al-MahmoodTamara Minko
Jul 4, 2018·Annals of Surgical Oncology·David W OllilaSheldon Feldman
Oct 23, 2019·Cancer Imaging : the Official Publication of the International Cancer Imaging Society·Sarah L SavaridasAndy Evans

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.